🧂 Salt Disproportionation Risk in Formulation

Microenvironmental pH and the pHmax Concept

Salt disproportionation is the reversion of an ionized drug salt back to its neutral, typically far less soluble, free acid or free base form while sitting inside a finished dosage form. The phenomenon is governed by a deceptively simple physicochemical idea — pHmax — but its real-world trigger is the microenvironmental pH (pHM) that drug particles actually experience at the solid-excipient-moisture interface, which can differ by several pH units from what a formulator might assume.

• 4–6: Typical basic-drug-salt pHmax (HCl, mesylate, besylate salts)
• 10–1000×: Solubility drop, salt→free base (common magnitude)
• slurry pH: pHM probe method (1 g solid : 1 mL water, USP approach)
• >60% RH: Disproportionation onset RH (moisture activates proton transfer)

The pHmax model — why a salt is not forever

For a weakly basic drug (BH+X−, e.g., an HCl salt), solubility as a function of pH follows the classic Henderson-Hasselbalch-derived pH-solubility profile:

At low pH: the drug exists predominantly as the ionized, protonated species (BH+), and total solubility ST is high and essentially pH-independent (governed by the salt's Ksp and common-ion effect from the counter-ion).

At high pH: the drug exists predominantly as the neutral free base (B), and solubility approaches the intrinsic solubility of the free base (S0), which for most drug-like molecules is 10- to 1000-fold lower than the salt form.

pHmax is the crossover pH at which the solubility of the salt-controlled region equals the solubility of the free-base-controlled region — above pHmax, the free base is the thermodynamically stable (least soluble) solid phase, and any salt present will, given enough time and available water, convert to free base.

pHmax = pKa + log10( [S0 × Ksp] / [X−]... ) — in practice, simplified working equations relate pHmax to the drug pKa, its intrinsic (free-form) solubility, and the salt solubility product; pHmax typically sits 1–3 pH units above the API pKa for HCl salts of moderately basic drugs.

The crucial formulation insight: pHmax is a property of the API-salt pair alone, independent of any specific excipient — but whether disproportionation actually happens in a real tablet depends entirely on whether the local pH experienced by the drug particle (pHM) exceeds this intrinsic pHmax value.

A weakly basic drug HCl salt with pHmax = 5.4 is, by definition, thermodynamically unstable as a salt in any aqueous microenvironment above pH 5.4 — including inside a tablet matrix that has absorbed atmospheric moisture and dissolved even a small fraction of an alkaline excipient.

Why microenvironmental pH (pHM) diverges from bulk pH

A dry tablet has no single "pH" in the classical sense — but as soon as trace atmospheric moisture is sorbed (routinely 1–5% w/w equilibrium moisture content even in nominally dry tablets at ambient RH), a thin, saturated aqueous microenvironment forms at the surface of every particle, and it is the pH of this microscopic film — not any bulk solution pH — that determines whether disproportionation proceeds.

Key factors that make pHM diverge sharply from what a naive pH measurement of the whole formulation would suggest:

• Localized excipient dissolution: an alkaline excipient particle sitting in intimate physical contact with a drug particle creates a highly concentrated, poorly buffered microdomain at their shared interface — the "bulk" tablet pH (if measurable at all) is largely irrelevant to what the drug particle itself experiences.

• Limited water availability: with only a few percent w/w moisture present, the aqueous microenvironment has very low buffer capacity and very small volume — a small quantity of dissolved alkaline excipient can swing pHM by several units, something that would be undetectable or heavily diluted in a bulk aqueous slurry measurement.

• Proximity-dependent risk: drug particles in direct contact with, or downstream (in the direction of moisture ingress) from, an alkaline excipient particle experience much higher pHM than particles isolated within an inert diluent matrix — this is why particle size, blend homogeneity, and granulation method materially affect disproportionation risk, not just formula-level excipient percentages.

The standard first-pass laboratory proxy for pHM is the slurry pH test (USP <1092>-informed): 1 gram of solid (drug, excipient, or blend) is slurried with 1 mL of water, mixed, and the pH measured after equilibration — a fast, simple, and surprisingly predictive screen for real disproportionation risk, though it is only a proxy for the true, far smaller and more concentrated in-tablet microenvironment.

Screening Alkaline Excipients That Elevate Microenvironmental pH

Most disproportionation risk in real formulations traces back to a small number of ubiquitous, functionally essential tableting excipients that happen to be mildly to moderately alkaline. Because these excipients cannot simply be removed from most formulations (magnesium stearate is present in the overwhelming majority of compressed tablets as a lubricant), compatibility screening must quantify — not merely flag — the magnitude of pH elevation each contributes.

• ~8–10: Mg stearate slurry pH (most common lubricant, alkaline)
• ~7–8: Croscarmellose Na slurry pH (residual NaOH from cross-linking)
• ~7–7.6: Dibasic Ca phosphate slurry pH (common high-dose diluent)
• ~2–3.5: Citric acid slurry pH (used as mitigating acidifier)

Why routine tableting excipients are alkaline

Excipient alkalinity is often an incidental consequence of the manufacturing chemistry used to produce the excipient itself, not a deliberate functional attribute:

• Magnesium stearate: a metallic soap (magnesium salt of stearic/palmitic acid) manufactured by reacting stearic acid with magnesium oxide or hydroxide; residual unreacted Mg(OH)2 and the inherently mildly alkaline character of the carboxylate soap give slurry pH values commonly in the 8–10 range. Because magnesium stearate is used as a lubricant in >90% of compressed tablets (typically 0.25–1.0% w/w) and characteristically coats granule/particle surfaces during blending (as a low-shear, hydrophobic film), it achieves outsized microenvironmental contact with drug particles despite its low bulk concentration.

• Croscarmellose sodium and sodium starch glycolate: both are cross-linked, sodium-salt superdisintegrants; the sodium carboxymethyl substitution and residual sodium hydroxide from the etherification/cross-linking process leave these excipients with slurry pH values of roughly 6.5–8, with meaningful lot-to-lot variability that itself becomes a formulation risk factor.

• Dibasic calcium phosphate (calcium hydrogen phosphate): a very common high-dose diluent/filler; being the conjugate base of phosphoric acid's second ionization, its aqueous slurry is mildly alkaline (pH ~7–7.6).

• Talc and colloidal silicon dioxide: generally near-neutral to mildly alkaline depending on grade and surface treatment, but far less potent pH-modifying agents than the excipients above.

Designing a systematic drug-excipient compatibility screen

A rigorous compatibility program directly tests, rather than assumes, each excipient's disproportionation risk against the specific API salt:

1. Binary slurry pH mapping: measure slurry pH for each individual excipient (1:1 solid:water w/w, per USP <1092> general guidance) and record against the API salt's known pHmax — this single data point already flags excipients whose slurry pH exceeds pHmax as high a priori risk.

2. Binary drug-excipient blends under accelerated stress: physical 1:1 (or use-level ratio) blends of drug salt with each excipient are stored open-dish at 40°C/75% RH (ICH Q1A(R2) accelerated condition) and pulled at intervals (2, 4, 8, 12 weeks) for PXRD to directly detect free-form crystallization — this is the single most decisive experimental readout, since it tests the real solid-state interaction rather than an aqueous proxy.

3. Ranking by both severity and use-level exposure: an excipient with only modestly alkaline slurry pH but present at 30–50% w/w (e.g., dibasic calcium phosphate as primary diluent) may pose greater aggregate risk than a strongly alkaline excipient present at only 0.5% w/w — total alkaline "buffering capacity" delivered into the microenvironment matters as much as peak pH.

4. Interaction with moisture-generating excipients: excipients that are themselves hygroscopic (certain disintegrants, some binders) amplify disproportionation risk from co-blended alkaline excipients by increasing the amount of water available to form the reactive microenvironmental film in the first place.

A well-documented industry case pattern: a weakly basic drug HCl salt formulated with magnesium stearate lubricant showed clear PXRD evidence of free-base conversion within 4–8 weeks at 40°C/75% RH, while an otherwise identical formulation using a non-alkaline lubricant (e.g., sodium stearyl fumarate, which has a much lower slurry pH) remained phase-pure across the same stress period — illustrating that lubricant selection alone can be the deciding CMC variable.

Slurry and Tablet Studies with PXRD/Raman Monitoring for Free-Form Conversion

Predictive slurry-pH screening and risk theory must ultimately be confirmed with real accelerated stability data on the actual (or representative prototype) formulation. PXRD remains the gold-standard technique for unambiguous free-form detection, while Raman chemical mapping adds spatially-resolved information about exactly where within a tablet the conversion is occurring — often revealing that disproportionation is highly localized around specific excipient particles rather than uniform throughout the matrix.

• ~2–5%: PXRD detection limit, free form (w/w, well-crystallized phase)
• ~1 µm: Raman mapping spatial resolution (confocal Raman microscopy)
• 40°C/75% RH: ICH accelerated condition (open-dish, 6-month standard)
• 2, 4, 8, 12, 26 wk: Typical monitoring interval (pull points for PXRD/HPLC)

Design of binary slurry and full-tablet accelerated stability studies

Two complementary study designs are run in parallel, moving from simplified to fully representative conditions:

Binary drug-excipient slurry/blend studies (mechanistic, high-sensitivity): • Physical powder blends (drug salt + single excipient, or drug salt + full excipient blend minus drug) at use-level ratios, sometimes with a small amount of added water to mimic worst-case moisture exposure, are stored in open dishes at 40°C/75% RH. • Because there is no tablet matrix diluting or physically separating particles, these studies represent a worst-case, high-sensitivity screen — useful for early risk ranking and mechanistic understanding, but can overestimate real in-tablet risk if the excipient in question is present at low use-level concentration.

Full prototype tablet/capsule studies (realistic, decision-enabling): • Actual compressed tablets or filled capsules from the candidate formulation are placed on stability per ICH Q1A(R2): accelerated (40°C/75% RH, 6 months) and long-term (25°C/60% RH or 30°C/65% RH, 12–24 months) conditions, typically in the intended primary packaging as well as open-dish (worst case) configurations. • Pull points (commonly 2, 4, 8, 12, and 26 weeks for accelerated) generate samples for PXRD, assay/related substances by HPLC, dissolution testing, and (for high-risk formulations) Raman mapping.

2. Analytical endpoints tracked at each pull point: • PXRD: appearance/growth of free-form-specific diffraction peaks (2θ positions unique to the free acid/base polymorph, established from a reference free-form standard run separately). • Dissolution: even before free-form crystallinity is detectable by PXRD, a measurable drop in dissolution rate/extent can be an earlier, more sensitive indicator of incipient disproportionation (amorphous or sub-crystalline free-form material still reduces effective solubility). • HPLC assay/related substances: confirms disproportionation (a physical form change) is not being conflated with chemical degradation (a covalent change) — both can reduce measured potency of the intact salt but require entirely different mitigation strategies.

Raman chemical mapping — visualizing where disproportionation occurs

Confocal Raman microscopy provides something PXRD (a bulk, spatially-averaged technique) cannot: a spatially resolved chemical map of a tablet cross-section or intact surface, showing precisely where free-form material has appeared relative to individual excipient particles.

Method: 1. A tablet cross-section is prepared (typically by careful cutting or polishing to expose an internal face without inducing new phase transformations from mechanical/thermal stress). 2. A confocal Raman microscope rasters a focused laser spot (spatial resolution roughly 1 µm, limited by diffraction) across a defined area, collecting a full Raman spectrum at each pixel (a "hyperspectral" data cube). 3. Reference spectra for the pure salt form, pure free form, and each major excipient are used to build a classification/unmixing model (e.g., classical least squares or cosine-correlation mapping) that assigns each pixel a probability/intensity for each chemical species present. 4. The resulting false-color chemical map directly visualizes free-form "hot spots" — and in well-documented case studies these hot spots correlate tightly with the spatial location of alkaline excipient particles (e.g., a halo of free-form signal surrounding magnesium stearate domains), providing direct mechanistic confirmation of the pHM-driven disproportionation model rather than a spatially uniform bulk conversion.

Raman mapping is typically reserved for confirmatory, mechanistic investigations (root-cause analysis of an observed PXRD signal, or supporting a formulation redesign decision) rather than routine batch-release testing, given its far higher time and instrument cost per sample compared to bulk PXRD.

In several published industry case studies, Raman mapping of stressed tablets showed free-base conversion concentrated almost exclusively within a ~5–20 µm halo surrounding individual magnesium stearate particles, with drug particles more than ~50 µm from any lubricant domain remaining essentially unconverted — direct microscopic proof that disproportionation risk is a local, particle-contact phenomenon, not a bulk-average one.

Building an Excipient Basicity vs. pHmax-Gap Risk Assessment Matrix

Once slurry pH data, compatibility stress-test results, and (where available) Raman confirmation are in hand, formulation scientists consolidate everything into a quantitative risk assessment matrix — plotting each excipient's basicity against the API salt's pHmax gap to rank formulation-level risk before committing to a full stability program, in line with ICH Q9 Quality Risk Management principles.

• 2: Risk matrix axes (excipient basicity × pHmax gap)
• 3: Typical risk tiers (low / medium / high)
• Q9: ICH guidance framework (Quality Risk Management)
• ΔpH < 1: Key gap threshold (unit margin flagged high-risk)

Constructing the risk matrix — axes, scoring, and interpretation

The disproportionation risk matrix is built on two independent, empirically measurable axes:

X-axis — Excipient basicity (slurry pH, or a use-level-weighted "alkaline load" score that also accounts for excipient concentration in the formula, since a mildly alkaline excipient present at high use-level can deliver comparable total alkaline capacity to a strongly alkaline excipient present at trace level).

Y-axis — pHmax gap: defined as (excipient/blend slurry pH) − (API salt pHmax). A positive gap (excipient pH exceeds pHmax) indicates thermodynamic favorability for disproportionation; the magnitude of the positive gap correlates (though not perfectly, since kinetics also matter) with how readily conversion proceeds within a realistic shelf-life timeframe.

Risk tiering (typical industry convention): • Low risk: pHmax gap <0 (excipient pH below salt pHmax) — thermodynamically the salt remains the stable form even in direct particle contact; residual risk mainly from unusual local concentration effects. • Medium risk: pHmax gap 0 to +1 pH unit — thermodynamically favorable but kinetically slow conversion is plausible; typically requires accelerated stability confirmation and may be acceptable with monitoring/mitigation depending on API dose and PK sensitivity to solubility loss. • High risk: pHmax gap >+1 pH unit, especially combined with high excipient use-level (>5% w/w) and/or direct physical contact in the manufacturing process (e.g., excipient used as an external lubricant coating drug-containing granules) — generally requires proactive mitigation before proceeding to pivotal stability batches.

This matrix is explicitly framed within the ICH Q9 Quality Risk Management structure: it feeds a formal risk assessment (severity × probability × detectability) that becomes part of the formulation development report and, ultimately, supports CMC justification in a regulatory submission.

Beyond static pH — incorporating kinetics, dose, and clinical impact into the assessment

A purely thermodynamic pHmax-gap score is a necessary but incomplete risk driver; a complete assessment layers in several additional dimensions:

• Conversion kinetics: some disproportionation reactions proceed to completion within weeks even at modest pHmax gaps (particularly for salts with high aqueous solubility and low crystallization energy barriers for the free form), while others remain kinetically trapped for years despite a thermodynamically unfavorable gap — accelerated stability data, not gap magnitude alone, ultimately governs the final risk call.

• Dose and therapeutic index sensitivity: for a high-solubility, wide-therapeutic-index drug, a modest (e.g., 10–20%) loss of effective dissolved fraction from partial disproportionation may have negligible clinical consequence; for a narrow-therapeutic-index or already borderline-BCS-Class-II/IV compound, the same degree of conversion could be clinically meaningful — risk tolerance is therefore drug-specific, not just formulation-specific.

• Manufacturing process contact intensity: high-shear wet granulation, which intimately co-processes drug and excipients in the presence of substantial water, generally poses higher disproportionation risk than direct compression or dry blending with minimal moisture exposure — process selection is itself a risk-mitigating (or risk-amplifying) formulation decision.

• Detectability and control strategy: even a medium- or high-risk formulation may be acceptable if a robust, validated analytical control (routine PXRD or dissolution monitoring at release and on stability) reliably detects unacceptable conversion before it reaches a clinically meaningful level — risk assessment under ICH Q9 explicitly weighs detectability alongside severity and probability.

A formulation combining a salt with a narrow pHmax gap (weak intrinsic protection), high-use-level alkaline diluent, wet granulation processing, and a narrow therapeutic index drug represents a "worst-case stack" that should trigger proactive mitigation during early development, well before committing to registration stability batches — retrofitting a formulation after a disproportionation signal appears in pivotal stability data is far costlier than designing it out upfront.

Formulation Mitigation Strategies for Disproportionation Risk

Once a formulation is flagged medium- or high-risk, several well-established mitigation levers are available — ranging from simple excipient substitution to more involved engineering solutions like functional coatings or alternative salt/cocrystal selection. Mitigation strategy selection depends on the magnitude of the pHmax gap, the manufacturing process already locked in, and how far along the development program has progressed.

• 1–10%: Acidifying excipient dose range (w/w, citric/tartaric/fumaric acid)
• 10–40 µm: Barrier coating thickness (typ. functional/isolation coat)
• D90 <50 µm: Particle size reduction target (reduces local contact area, mixed effect)
• 5–15: Alternative salt screening pool (counter-ions typically evaluated)

Acidifying excipients and microenvironmental pH modifiers

The most direct mitigation is deliberately incorporating an acidifying excipient into the formulation to counteract the alkaline contribution of essential excipients like magnesium stearate:

• Organic acids (citric, tartaric, fumaric, succinic, adipic acid) are added at 1–10% w/w, either blended directly with the alkaline excipient of concern or, more effectively, granulated intimately with the drug substance so that the acidifying agent is co-located with drug particles rather than segregated elsewhere in the blend.

• Mechanism: the acidifying excipient locally buffers the microenvironmental water film toward lower pH, keeping pHM below the salt's pHmax even in the presence of an alkaline lubricant or diluent elsewhere in the tablet.

• Practical considerations: the acidifying agent must itself be chemically compatible with the API (no unwanted acid-catalyzed degradation, e.g., ester hydrolysis or Maillard-type reactions with certain excipients), and its own hygroscopicity/deliquescence behavior must be assessed, since some organic acids (e.g., citric acid) are themselves quite hygroscopic and could increase overall formulation moisture uptake — a secondary risk factor for disproportionation.

• Buffer capacity matching: the quantity of acidifying agent needed scales with the alkaline "load" being counteracted (excipient basicity × use-level), not simply a fixed percentage — formal buffer-capacity calculations or empirical slurry-pH titration of prototype blends are used to right-size the acidifying excipient level.

Physical separation, particle engineering, and process controls

When chemical (pH-modifying) mitigation alone is insufficient or undesirable, physical/engineering strategies reduce the intimacy of contact between drug particles and alkaline excipients:

• Functional or isolation film coating: drug-layered pellets, granules, or even individual crystals can be coated with a thin (10–40 µm) polymeric barrier (e.g., hydroxypropyl methylcellulose, ethylcellulose, or an enteric polymer selected for chemical compatibility) before blending with the alkaline excipient — physically preventing direct particle-particle contact and moisture-mediated pH communication.

• Granulation strategy: incorporating the alkaline excipient (e.g., using it as an intragranular rather than extragranular component, or vice versa) changes which particles are in direct contact during the critical wet-processing and drying steps; extragranular addition of magnesium stearate (added only at the final lubrication blending step, briefly and at low shear) generally reduces disproportionation risk compared to intragranular incorporation during wet granulation.

• Lubricant alternative selection: replacing magnesium stearate with a non-alkaline lubricant such as sodium stearyl fumarate (slurry pH much closer to neutral) is one of the most effective and simplest single mitigations when disproportionation is lubricant-driven, though it requires re-evaluating tablet compaction/ejection performance since lubricant efficiency differs between agents.

• Particle size and surface area control: reducing drug particle size generally increases dissolution rate (a formulation benefit) but simultaneously increases specific surface area available for disproportionation reaction at the particle-excipient interface — this is a genuine trade-off requiring case-by-case evaluation rather than a universal rule.

• Moisture control: reducing formulation equilibrium moisture content (tighter in-process drying endpoints, use of a lower-hygroscopicity excipient set, or moisture-protective primary packaging with desiccant) directly limits the aqueous microenvironment available to drive proton transfer, addressing the root physical trigger rather than only the pH driver.

Alternative salt, cocrystal, or amorphous form selection as an upstream fix

When disproportionation risk is severe and formulation-level mitigation proves insufficient, the most robust (though most resource-intensive) fix is addressing the problem upstream, at the solid-form selection stage, before formulation development is far advanced:

• Alternative counter-ion (salt) screening: different salt forms of the same API (e.g., besylate, mesylate, tosylate, fumarate, maleate instead of hydrochloride) can have substantially different pHmax values, since pHmax depends on the specific solubility product of the salt, not only on the API's intrinsic pKa — a salt screen of 5–15 counter-ions is a standard early-development activity specifically to identify a form with a wider (safer) pHmax margin relative to expected formulation microenvironmental pH.

• Co-crystal alternatives: as explored in synthon-based co-crystal engineering, a pharmaceutical co-crystal can sometimes provide solubility and dissolution advantages similar to a salt without the same ionization-driven pH-dependent reversion mechanism, since co-crystal stability is governed by hydrogen-bond lattice energetics rather than simple proton-transfer equilibrium — though co-crystals carry their own distinct stability risk profile (dissociation back to the individual components under different stress conditions) that must be separately evaluated.

• Amorphous solid dispersion (ASD): for select high-risk cases, formulating the free-form API as an amorphous solid dispersion (e.g., via spray-drying or hot-melt extrusion with a polymer such as HPMCAS or PVP-VA) can achieve high apparent solubility without relying on a salt form at all, sidestepping the disproportionation mechanism entirely — at the cost of introducing a different stability risk (physical recrystallization of the amorphous phase) that requires its own dedicated control strategy.

The most cost-effective point to address disproportionation risk is always the earliest one: a salt/cocrystal screen conducted during pre-formulation, informed by realistic excipient pHmax-gap modeling, can eliminate a risk that would otherwise require expensive, time-consuming formulation rework (or in the worst case, a field alert / product recall) after the issue surfaces in registration stability data or, worse, post-approval commercial stability monitoring.